SIGMA Stakeholder Announcement

Share on: 

Launch of the SIGMA Consortium heralds a new era of collaboration to better understand safety and effectiveness of medical interventions. Research institutions compete for resources to carry out research. SIGMA aims to address this challenge by integrating expertise and data from multiple European Research Centres. The new collaborative research initiative, designed to be the best ‘go-to’ organisation for comprehensive and rigorous methodological research, is being launched to enable multi-country studies using common analyses to study responses to treatments in large populations.

SIGMA executive committee start up members Professor Ron Herings (Netherlands) and Dr. Susana Perez-Gutthann (Spain) said “The benefits and risks of treatments are of concern to every citizen. Our objective is to clarify and quantify these treatment effects for the citizens of Europe.”

The SIGMA Consortium’s VISION is to provide best evidence on the use, benefits and harms of medications, vaccines and devices for the betterment of public health and patient care. Its MISSION is to provide trusted pharmacoepidemiologic and real-world evidence (PE/RWE) research through a European federated professional network of excellence based on the ENCePP Code of Conduct. The SIGMA consortium welcomes collaborations with other groups and networks. 

The SIGMA Consortium is formed by a group of leading research institutions and Universities with extensive expertise and experience in the conduct of pharmacoepidemiologic and real-world evidence research:

Country

Institution

Lead

Denmark

Aarhus University, Department of Clinical Epidemiology

Prof. Vera Ehrenstein

Denmark

University of Southern Denmark, Department of Clinical Pharmacology and Pharmacy

Prof. Jesper Hallas, FISPE

France

University of Bordeaux’s Bordeaux PharmacoEpi Platform

Prof. Nicholas Moore, FISPE

Germany

Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH

Prof. Ulrike Haug

Italy

Agenzia Regionale di Sanità (ARS Toscana)

Dr. Rosa Gini

Netherlands

PHARMO Institute for Drug Outcomes Research

Prof. Ron Herings, FISPE

Netherlands

University Medical Centre Utrecht (UMCU)

Prof. Miriam Sturkenboom, FISPE

Netherlands

Utrecht University Division of Pharmacoepidemiology & Clinical Pharmacology

Prof. Olaf Klungel, FISPE

Spain

Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol)

Dr. Maria Giner

Spain/USA

RTI Health Solutions

Dr. Susana Perez-Gutthann, FISPE

United Kingdom

University of Dundee, Scotland

Prof. Thomas MacDonald, FISPE

SIGMA Model of collaboration: 

SIGMA Collaboration Model

Adapted from VAC4EU (https://vac4eu.org/decision-making-and-roles-in-the-conduct-of-studies/)

Study funder institutions can contact the Sigma Consortium Office or a Sigma member organization. The request will be distributed to all Sigma members to express interest and availability to participate in the study in the roles of Coordinating Centre, Principal Investigator Centre and/or Research Site. 

For more information, please contact 
Josine Kuiper or Carla Franzoni at the SIGMA Office (info@sigmaconsortium.eu)

 

Related Services:
Staff Members: